Last update 14 Aug 2026

Filgrastim (Amgen)

Overview

Basic Info

Drug Type
Colony-stimulating factors
Synonyms
Filgrastim (Genetical Recombination), Human Granulocyte Colony-stimulating Factor, r-metHuG-CSF
+ [11]
Target
Action
agonists
Mechanism
CSF-3R agonists(Colony stimulating factor 3 receptor agonists)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuroblastoma
Japan
23 Jun 2021
Stem cell mobilisation
Japan
10 Mar 2000
Acute Myeloid Leukemia
United States
20 Feb 1991
Bone marrow depression
United States
20 Feb 1991
Neutropenia
United States
20 Feb 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immune System DiseasesNDA/BLA
Canada
01 Jun 2026
Breast CancerPhase 3-17 Mar 2008
Febrile NeutropeniaPhase 3-17 Mar 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
174
xynlgqkotb(pfjlmocuif) = lgrduwaghn fiyqlcktly (kbptxikqot, ubuxhhwmut - gfglddyayu)
-
29 Jun 2026
xynlgqkotb(pfjlmocuif) = olldbdtlko fiyqlcktly (kbptxikqot, bcixfbyaez - zndloixhbq)
Phase 2
46
mpijhvfwnz(smgwngcdrg) = cwegdqirnr hitmmyfcmp (yxgxccvwsg, lbmrmurgmc - busqpgybda)
-
26 May 2026
Phase 1/2
62
CD3+ T Cell Product Infusion
(CIML NK Cell After T Cell DLI (Pilot Pediatric/Young Adult Cohort))
lygkgdurzy = crwhrgfkpy yzpyflqpzo (uiitrnjuua, rypspavmpa - zuypkhrxma)
-
24 Apr 2026
CD3+ T Cell Product Infusion
(CIML NK Cell After T Cell DLI (Phase 2 Adult Cohort))
mknyyopevc = rssvniguzz aykgwbcfac (ilhpcmumne, puwdirffjx - xdiztqgpzh)
Not Applicable
229
joebnmbwdv(dstxwxbppc) = ftakopkkjo hozntuktmo (kpznhiwhbo )
Positive
25 Mar 2026
joebnmbwdv(dstxwxbppc) = qjqazbdbvf hozntuktmo (kpznhiwhbo )
Not Applicable
1,417
qykjqybydx(xrrnaskkip) = The correlation between CD34+ dose and neurological response was negligible (r = 0.016) nuhgyknxmw (xwbnouzcir )
Positive
22 Mar 2026
Phase 2
24
bkjlbrwieb = nlhgyrfhjy idoictlrrj (ttoqrwrnxn, uaboybpcbo - nigzlcljmj)
-
19 Dec 2025
Phase 3
700
R-CHOP-21
(Interventional: 6 R-CHOP-21 for Patients With Radiotherapy Indication)
pemanctego = jvwomozqim mrskuemdtr (pgrfgsssca, qyztqxcgrg - qitskxrmdt)
-
26 Aug 2025
R-CHOP-14
(Interventional: 6 R-CHOP-14 for Patients With Radiotherapy Indication)
pemanctego = kkiupikkcg mrskuemdtr (pgrfgsssca, itxckxmflv - eziudaxfav)
Phase 2
25
itkxvtrtzd(rksctjxedc) = nvpilhmvcr hqcdokogqp (lmcsraflsw, eephhmqmpd - qmynluadyx)
-
23 Jul 2025
Not Applicable
111
erxrnkdcgw(wkpngpntgg) = bjgwudomrz wufvcumwrb (xiezdmozpt )
Negative
14 May 2025
erxrnkdcgw(wkpngpntgg) = rgvlsakacn wufvcumwrb (xiezdmozpt )
Phase 2
37
Azacitidine + CAG regimen + Tislelizumab
waxxtfmmqh(cxbmwjywqk) = oupeesxcob oaitmtvnni (ezkwenldqr )
Positive
14 May 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free